CJC-1295 DAC vs No DAC: What’s the Difference?

CJC-1295 with DAC binds albumin and persists for days; the no-DAC version (Mod GRF 1-29) lasts minutes. Structure, molecular weight, published data and how to tell them apart on a COA.

Two different peptides are sold under the name CJC-1295. One carries a Drug Affinity Complex (DAC) that lets it bind serum albumin; the other does not, and is more accurately called Modified GRF (1-29). They differ in structure, molecular mass and how long they persist in published studies, so knowing which one is in a vial matters before any experiment is designed.

In short

CJC-1295 with DAC and CJC-1295 without DAC share the same 29-residue GHRH analog backbone. The DAC version adds a maleimidopropionyl-lysine at position 30 (about 3,647 Da) that binds albumin, and its reported human half-life is 5.8–8.1 days. The no-DAC version, Modified GRF (1-29), weighs about 3,368 Da and has a reported half-life of around 30 minutes.

Holiday sale: every research compound is buy one, get one free through December 25, 2026 — sitewide, unlimited, applied automatically at checkout. See how it works.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the 44-residue hypothalamic peptide that stimulates growth hormone (GH) release from pituitary somatotrophs. Its design starts from GHRH (1-29)-NH2, the shortest fragment that keeps full receptor activity, also known by the drug name sermorelin.

Native GHRH (1-29) is short-lived. In plasma it is cleaved between Ala2 and Asp3 by dipeptidyl peptidase-4, producing an inactive fragment; Frohman and colleagues described this rapid N-terminal degradation in 1986, and published half-life estimates for GRF (1-29) are under 10 minutes. CJC-1295 was developed by ConjuChem to solve that problem in two steps, and the confusion over its name comes from the fact that the two steps are now sold separately.

What is the difference between CJC-1295 with DAC and without DAC?

The only structural difference is the DAC: an extra lysine at position 30 whose side chain carries a maleimidopropionyl group. Everything else is shared.

  • Step 1, the tetrasubstituted backbone (both versions). Four substitutions on GRF (1-29): D-Ala2 (resists DPP-4 cleavage), Gln8 (replaces Asn, which is prone to deamidation), Ala15 (replaces Gly) and Leu27 (replaces Met, which oxidizes). This peptide on its own is Modified GRF (1-29), often sold as “CJC-1295 no DAC”.
  • Step 2, the Drug Affinity Complex (DAC version only). Lys30-Nε-maleimidopropionyl. The maleimide reacts with the free thiol of Cys34 on serum albumin in vivo, as shown in animal and human studies, tethering the peptide to a carrier with a long circulating life.
Property CJC-1295 with DAC CJC-1295 no DAC (Mod GRF 1-29)
Length 30 residues + maleimidopropionyl group 29 residues
Molecular formula C165H269N47O46 C152H252N44O42
Average molecular weight ~3,647.3 g/mol ~3,367.9 g/mol (free base)
Binds albumin covalently Yes, via maleimide No
Reported half-life 5.8–8.1 days (healthy adults, Teichman 2006) At least ~30 minutes (vs <10 min for GRF 1-29)
GH secretion pattern in studies Sustained rise in trough GH; pulses preserved Short pulse-like release

The roughly 279 Da gap between the two masses equals the added lysine plus the maleimidopropionyl group. That number is the most practical way to tell the two apart, as covered below.

Why does the DAC change the half-life so much?

The DAC changes half-life by handing the peptide to albumin. Human serum albumin circulates for about three weeks and is too large for renal filtration, so a peptide covalently bound to it is protected from both kidney clearance and much of its proteolysis.

Jetté and colleagues (2005) built a series of GRF (1-29)-albumin bioconjugates and tested them in rats, identifying CJC-1295 as the analog that kept GRF receptor activity on the anterior pituitary while producing long-lasting effects. Without the DAC, Modified GRF (1-29) still benefits from its four stabilizing substitutions, which is why its reported half-life (about 30 minutes) is several times longer than native GRF (1-29), but it is cleared within hours rather than days.

What did the published studies on CJC-1295 with DAC find?

The human data come from a small number of ConjuChem-sponsored studies in healthy adults, plus animal work. In summary:

  • Teichman et al., 2006 (J Clin Endocrinol Metab). Two randomized, placebo-controlled, double-blind ascending-dose studies in adults aged 21–61. A single administration raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9–11 days. The estimated half-life was 5.8–8.1 days, and with repeated administration IGF-I stayed above baseline for up to 28 days.
  • Ionescu and Frohman, 2006 (J Clin Endocrinol Metab). Overnight sampling every 20 minutes in healthy men aged 20–40, one week after a single administration. GH pulse frequency and amplitude were unchanged, while trough GH rose 7.5-fold, mean GH 46% and IGF-I 45%. The authors concluded the rise in basal GH, not larger pulses, accounted for the IGF-I increase.
  • Alba et al., 2006 (Am J Physiol Endocrinol Metab). In GHRH knockout mice, administration every 24 hours for 5 weeks normalized body weight and length, while 48- or 72-hour intervals were only partly effective. Pituitary GH mRNA increased and histology suggested somatotroph proliferation.

Clinical development was halted in 2006 after a participant in a phase II study died. The attending physician attributed the death to pre-existing coronary artery disease and judged it unrelated, but the program was not resumed, and CJC-1295 has never been approved as a drug in any jurisdiction.

Why do researchers still work with the no-DAC version?

Researchers use Modified GRF (1-29) when they want GHRH receptor activation that starts and stops on a short timescale. The Ionescu data show the DAC version produces a continuous elevation of trough GH, which is a different signal from the episodic pattern of native GHRH. For experiments designed around discrete stimulation, or for comparisons with ghrelin-receptor agonists such as ipamorelin, a short-acting GHRH analog is the cleaner tool.

This is also the reason GHRH analogs and ghrelin mimetics are so often studied together: they act on different pituitary receptors (GHRH-R and GHS-R1a). Our tesamorelin and ipamorelin guide covers a related pairing, and the CJC-1295 + Ipamorelin blend supplies the two in one vial for in vitro work.

How can you tell which CJC-1295 is in a vial?

Check the mass spectrometry result on the certificate of analysis. The label alone is unreliable: large reagent suppliers use the name “CJC-1295” for the no-DAC peptide, while the original literature uses it for the DAC conjugate.

  • Read the observed mass. A molecular ion consistent with about 3,647 Da indicates the DAC version; about 3,368 Da indicates Modified GRF (1-29). ESI spectra show several charge states (for example [M+3H]3+ and [M+4H]4+), which should deconvolute to one of those values. See peptide molecular weight and net peptide content.
  • Check the sequence and formula listed. A sequence ending in “-Ser-Arg-NH2” is the no-DAC peptide; one ending in “Lys(maleimidopropionyl)-NH2” is the DAC version.
  • Read HPLC purity separately. Purity says how much of the sample is the main peak, not which peptide that peak is. Our guide to reading a peptide COA explains both measurements.
  • Match the lot number. The COA should cover the lot printed on the vial. Soraci Labs publishes third-party results on the COA page.

How should CJC-1295 be stored and handled in the lab?

Store lyophilized CJC-1295 of either type at −20 °C, dry and protected from light, which is the condition reagent suppliers list for the no-DAC peptide. The DAC version needs extra care after reconstitution: its maleimide is reactive toward thiols and slowly hydrolyzes in aqueous solution, especially above neutral pH, so buffers containing DTT, β-mercaptoethanol or other free thiols will consume it. General guidance on temperature, freeze-thaw cycles and degradation pathways is in our peptide storage and stability guide.

Frequently asked questions

Is CJC-1295 the same as Mod GRF 1-29?
Not strictly. In the original literature CJC-1295 is the DAC conjugate. Modified GRF (1-29) is the same 29-residue tetrasubstituted backbone without the DAC, but many suppliers sell it as “CJC-1295 no DAC” or simply “CJC-1295”.
What does DAC stand for in CJC-1295?
DAC stands for Drug Affinity Complex, ConjuChem’s name for a maleimidopropionyl group on an added C-terminal lysine. It binds covalently to Cys34 of serum albumin, which extends the peptide’s half-life from minutes to days.
What is the half-life of CJC-1295 with DAC versus without DAC?
Teichman et al. (2006) estimated 5.8–8.1 days for the DAC version in healthy adults. Modified GRF (1-29) is reported at roughly 30 minutes or more, against under 10 minutes for unmodified GRF (1-29).
What is the molecular weight of CJC-1295?
About 3,647.3 g/mol for CJC-1295 with DAC (C165H269N47O46) and about 3,367.9 g/mol for the no-DAC peptide (C152H252N44O42). The difference of roughly 279 Da is the easiest way to distinguish them on a mass spectrum.
Does CJC-1295 with DAC stop natural GH pulses?
In the one study that measured it, no. Ionescu and Frohman (2006) found GH pulse frequency and amplitude unchanged one week after administration in healthy men, while trough GH rose 7.5-fold.
Is CJC-1295 an approved drug?
No. Its clinical development was discontinued in 2006 and it has not been approved by the FDA or any other regulator. It is available only as a research compound.

References

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. doi:10.1210/jc.2005-1536. PMID 16352683. PubMed
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. doi:10.1210/jc.2006-1702. PMID 17018654. PubMed
  3. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290–E1294. doi:10.1152/ajpendo.00201.2006. PMID 16822960. PubMed
  4. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. doi:10.1210/en.2004-1286. PMID 15817669. PubMed
  5. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906–913. PMID 3093533. PubMed
  6. Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021;13(11–12):1871–1887. doi:10.1002/dta.3183. PMID 34665524. PubMed

Compound data: CJC-1295 (with DAC) molecular formula and mass as listed in public chemical databases; no-DAC formula and formula weight from Cayman Chemical item 32704 product data.

All Soraci Labs products are sold for laboratory, analytical and research purposes only. They are not intended for human consumption, medical use, diagnostic use, or the treatment of any disease or condition.

Leave a Reply

Your email address will not be published. Required fields are marked *